Agios Pharmaceuticals Cash Flow Statement
NASDAQ: AGIOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
31.81-0.11 (-0.34%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Agios Pharmaceuticals free cash flow
In fiscal 2025, Agios Pharmaceuticals generated -$373.0 million of operating cash flow and spent $4.3 million on capital expenditures. That left free cash flow of -$377.3 million, a free-cash-flow margin of -698.3% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Agios Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -412.78M | 673.73M | -352.09M | -231.80M | 1.60B | -327.37M | -411.47M | -346.03M | -314.67M | -198.47M |
| Net Income growth (YoY) | -161.27% | — | — | -114.44% | — | — | — | — | — | — |
| Depreciation & Amortization | 5.20M | 5.70M | 6.60M | 8.40M | 8.80M | 9.40M | 8.09M | 7.17M | 6.43M | 5.71M |
| Stock-Based Compensation | 52.55M | 42.85M | 44.77M | 49.30M | 53.51M | 61.60M | 58.05M | 73.36M | 47.81M | 42.09M |
| Change in Working Capital | -13.99M | -9.32M | -18.21M | -4.43M | -24.98M | 3.33M | -6.05M | -5.21M | -21.91M | 167.20M |
| Operating Cash Flow | -372.98M | -389.84M | -296.06M | -309.48M | -407.32M | -290.76M | -370.62M | -304.42M | -285.23M | 38.56M |
| Capital Expenditures | -4.32M | -1.69M | -999.00K | -4.88M | -5.74M | -14.11M | -12.03M | -6.99M | -4.63M | -9.91M |
| Investing Cash Flow | 377.18M | 363.44M | 239.57M | 243.26M | 1.25B | 75.75M | 91.44M | -273.82M | -57.91M | -119.35M |
| Share Repurchases | — | — | 0 | 0 | -802.49M | 0 | 0 | — | — | — |
| Financing Cash Flow | 8.68M | 14.44M | 5.43M | 2.35M | -765.77M | 261.52M | 289.61M | 546.02M | 285.11M | 169.78M |
| Net Change in Cash | 12.88M | -11.96M | -51.05M | -63.87M | 75.69M | 46.51M | 10.43M | -32.22M | -58.03M | 88.99M |
| Free Cash Flow | -377.29M | -391.53M | -297.06M | -314.36M | -413.06M | -304.87M | -382.65M | -311.41M | -289.86M | 28.65M |
This table shows 10 annual periods of Agios Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AGIO's reporting calendar. What is a cash flow statement?